Amgen Inc. $AMGN Stock Position Boosted by Canada Post Corp Registered Pension Plan

Canada Post Corp Registered Pension Plan boosted its stake in Amgen Inc. (NASDAQ:AMGN) by 94.8% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 20,263 shares of the medical research company’s stock after buying an additional 9,863 shares during the period. Canada Post Corp Registered Pension Plan’s holdings in Amgen were worth $6,632,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the stock. 626 Financial LLC bought a new position in Amgen during the 4th quarter valued at $211,000. Arbor Trust Wealth Advisors LLC bought a new position in Amgen during the 4th quarter valued at $203,000. Cambridge Investment Research Advisors Inc. boosted its stake in Amgen by 2.1% during the 4th quarter. Cambridge Investment Research Advisors Inc. now owns 107,606 shares of the medical research company’s stock valued at $35,220,000 after purchasing an additional 2,177 shares in the last quarter. O Brien Greene & Co. Inc boosted its stake in Amgen by 0.3% during the 4th quarter. O Brien Greene & Co. Inc now owns 29,671 shares of the medical research company’s stock valued at $9,712,000 after purchasing an additional 85 shares in the last quarter. Finally, Hills Bank & Trust Co boosted its stake in Amgen by 44.4% during the 4th quarter. Hills Bank & Trust Co now owns 969 shares of the medical research company’s stock valued at $317,000 after purchasing an additional 298 shares in the last quarter. Institutional investors own 76.50% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts have issued reports on AMGN shares. TD Cowen reaffirmed a “buy” rating on shares of Amgen in a research note on Wednesday, February 4th. Barclays initiated coverage on shares of Amgen in a research report on Friday, February 20th. They set an “equal weight” rating and a $350.00 price objective for the company. Citigroup raised their price objective on shares of Amgen from $315.00 to $345.00 and gave the company a “neutral” rating in a research report on Wednesday, February 4th. Piper Sandler reduced their price objective on shares of Amgen from $432.00 to $427.00 and set an “overweight” rating for the company in a research report on Thursday. Finally, Canaccord Genuity Group initiated coverage on shares of Amgen in a research report on Monday, April 20th. They set a “hold” rating and a $366.00 price objective for the company. Two research analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating, fourteen have given a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat, Amgen has an average rating of “Hold” and a consensus target price of $356.15.

Insider Activity at Amgen

In related news, SVP Nancy A. Grygiel sold 1,237 shares of the firm’s stock in a transaction that occurred on Monday, May 4th. The shares were sold at an average price of $323.73, for a total transaction of $400,454.01. Following the completion of the sale, the senior vice president directly owned 7,009 shares in the company, valued at approximately $2,269,023.57. This trade represents a 15.00% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Corporate insiders own 0.85% of the company’s stock.

Amgen Stock Performance

Shares of Amgen stock opened at $326.31 on Friday. The stock has a market cap of $176.10 billion, a PE ratio of 22.71, a price-to-earnings-growth ratio of 3.28 and a beta of 0.44. The business has a fifty day simple moving average of $349.17 and a 200-day simple moving average of $342.99. The company has a quick ratio of 1.01, a current ratio of 1.26 and a debt-to-equity ratio of 5.65. Amgen Inc. has a 12 month low of $267.73 and a 12 month high of $391.29.

Amgen (NASDAQ:AMGN) last issued its earnings results on Thursday, April 30th. The medical research company reported $5.15 EPS for the quarter, topping the consensus estimate of $4.77 by $0.38. The business had revenue of $8.62 billion during the quarter, compared to analysts’ expectations of $8.58 billion. Amgen had a return on equity of 137.41% and a net margin of 20.96%.Amgen’s revenue was up 5.8% compared to the same quarter last year. During the same quarter last year, the firm posted $4.90 earnings per share. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS. On average, sell-side analysts anticipate that Amgen Inc. will post 22.37 EPS for the current fiscal year.

Amgen Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, June 5th. Investors of record on Friday, May 15th will be issued a dividend of $2.52 per share. This represents a $10.08 annualized dividend and a dividend yield of 3.1%. The ex-dividend date is Friday, May 15th. Amgen’s dividend payout ratio (DPR) is currently 70.15%.

Amgen Company Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.